Eli Lilly's GLP-1 Obesity Drug Shows Growing Promise in Phase 3 Trials

Eli Lilly has reported positive Phase 3 clinical trial results for its investigational obesity treatment, Retatrutide, with its latest GLP-1 drug showing significant promise as a powerful weapon in the fight against obesity.

24 May, 10:00 — 24 May, 10:00

Post Share

Sources

Showing 1 of 1 sources

wapoMostly Factual18d ago

The promise of weight-loss drugs keeps growing

Eli Lilly's latest GLP-1 drug could be yet another powerful weapon in the fight against obesity.

By Editorial Board

Read full article →

PERSPECTA

PERSPECTA

Eli Lilly's GLP-1 Obesity Drug Shows Growing Promise in Phase 3 Trials

Sources

The promise of weight-loss drugs keeps growing

Related Stories

Extreme Training: What Heat Training Does to the Body

Study Links Early Menopause to Increased Heart Attack, Stroke Risk

Dangers of Button Battery Ingestion Highlighted, European Register Established

First Aid Advice: Call 112 and Use Honey

PERSPECTA